Literature DB >> 2506511

[In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].

C J Soussy1, R Leclercq, L Deforges, J Duval.   

Abstract

Minimal inhibitory concentrations (MIC) of fleroxacin (FLE) were evaluated by agar dilution for 375 bacterial strains. For Enterobacteriaceae, MIC of FLE were (microgram/ml): nalidixic acid (NAL), susceptible (S), pefloxacin (PEF), susceptible (S) strains: 0.032 to 0.5; NAL, resistant (R), PEF S: 0.25 to 1; NAL R, PEF R: 1 to 32; NAL R, PEF R strains were particularly observed among Serratia marcescens and Providencia stuartii, Pseudomonas aeruginosa was less susceptible to FLE (MIC 1 to 4), as to PEF; two PEF R strains were inhibited by 32 micrograms/ml of FLE. FLE was active on A. baumannii PEF S strains (0.5), but this activity was reduced on PEF R strains (2 to 64). H. influenzae and N. meningitidis (0.03 to 0.06), N. gonorrhoeae (0.016 to 0.03) and L. pneumophila (0.03 to 0.25) were very susceptible to FLE. MIC of FLE on S. aureus were 0.25 to 1 for PEF S strains and greater than or equal to 16 for PEF R strains, also resistant to methicillin. Enterococci, Streptococci and Pneumococci were less susceptible to FLE (2 to 8). C. perfringens (0.5 to 1) appeared susceptible to FLE whereas B. fragilis was inhibited by higher concentrations (4 to 8). So, antibacterial properties of FLE are very similar to that of PEF; PEF R strains appear generally resistant to FLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506511

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  1 in total

1.  Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Haseeb Khaliq; Saeed Ahmed; Bowen Fan; Jiyue Cao; Qigai He
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.